[1] Aron-Wisnewsky J, VigliottiC, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol, 2020,17(5):279-297.
[2] Cazanave SC, Gores GJ. Mechanisms and Clinical Implications of Hepatocyte Lipoapoptosis. Clin Lipidol, 2010,5(1):71-85.
[3] Zhao P , Sun X , Chaggan C , et al. An AMPK-Caspase-6 Axis Controls Liver Damage in Nonalcoholic Steatohepatitis. Science, 2020,367(6478):652-660.
[4] Qian L , Ji J J , Jiang Y , et al. Serpina3c deficiency induced necroptosis promotes non-alcoholic fatty liver disease through β-catenin/Foxo1/TLR4 signaling. FASEB J, 2022,36(5):e22316.
[5] Zhang H, Zhou L, Zhou Y, et al. Intermittent hypoxia aggravates non-alcoholic fatty liver disease via RIPK3-dependent necroptosis-modulated Nrf2/NFκB signaling pathway. Life sciences, 2021, 285:119963.
[6] Galluzzi L , Vitale I , Aaronson SA , et al. Molecular Mechanisms of Cell Death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ, 2018,25(3):486-541.
[7] Murphy JM , Vince JE . Post-Translational Control of RIPK3 and MLKL Mediated Necroptotic Cell Death F1000res,2015 ,19:4.
[8] Sun L , Wang H , Wang Z , et al. Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase. Cell, 2012,148(1-2):213-227.
[9] Murphy J , Czabotar P , Hildebrand J , et al.The Pseudokinase MLKL Mediates Necroptosis via a Molecular Switch Mechanism. Immunity, 2013,39(3):443-453.
[10] Newton K , Wickliffe KE , Dugger DL , et al. Cleavage of RIPK1 by Caspase-8 Is Crucial for Limiting Apoptosis and Necroptosis. Nature, 2019,574(7778):428-431.
[11] Degterev A , Ofengeim D , Yuan J . Targeting RIPK1 for the Treatment of Human Diseases. Proc Natl Acad Sci U S A, 2019,116(20):9714-9722.
[12] Newton K, Manning G. Necroptosis and Inflammation. Annu Rev Biochem, 2016,85:743-763.
[13] Sarhan J, Liu BC, Muendlein HI, et al.Constitutive interferon signaling maintains critical threshold of MLKL expression to license necroptosis. Cell Death Differ, 2019,26(2):332-347.
[14] Sai K, Parsons C, House JS, et al.Necroptosis mediators RIPK3 and MLKL suppress intracellular Listeria replication independently of host cell killing. J Cell Biol, 2019,218(6):1994-2005.
[15] Rickard JA, O'Donnell JA, Evans JM, et al.RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell, 2014,157(5):1175-1188.
[16] Yang C, Li J, Yu L, et al.Regulation of RIP3 by the transcription factor Sp1 and the epigenetic regulator UHRF1 modulates cancer cell necroptosis. Cell Death Dis, 2017,8(10):e3084.
[17] Dara L , Liu ZX , Kaplowitz N. Questions and Controversies: The Role of Necroptosis in Liver Disease. Cell Death Discov,2016,2:16089.
[18] Dara L. The Receptor Interacting Protein Kinases in the Liver. Semin Liver Dis,2018,38(1):73-86.
[19] Cazanave SC , Gores GJ. Mechanisms and Clinical Implications of Hepatocyte Lipoapoptosis. Clin Lipidol, 2010,5(1):71-85.
[20] Harrison SA , Goodman Z , Jabbar A , et al. A randomized, placebo-controlled trial of emricasanin patients with NASH and F1-F3 fibrosis . J Hepatol, 2020,72(5):816-827.
[21] Maher, Jacquelyn J . Modeling Fatty Liver Disease in Animals: Is There an Optimal Approach, and Is the Effort Worthwhile? Hepatology, 2016,64(5):1398-1400.
[22] Jr Russell KS, Yan JS , Grenert JP , et al. Stress Signaling in the Methionine-Cholinedeficient Model of Murine Fatty Liver Disease. Gastroenterology, 2010,139(5):1730-9, 1739.e1.
[23] Imajo K, Yoneda M, Kessoku T, et al. Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Int J Mol Sci, 2013,14(11):21833-57.
[24] Santhekadur P, K , Kumar D, P , Sanyal A, J . Preclinical Models of Non-Alcoholic Fatty Liver Disease. J Hepatol,2018,68(2):230-237.
[25] Feldstein AE , Canbay A , Angulo P , et al. Hepatocyte Apoptosis and Fas Expression Are Prominent Features of Human Nonalcoholic Steatohepatitis. Gastroenterology, 2003,125(2):437-443.
[26] Thapaliya S , Wree A , Povero D , et al. Caspase 3 Inactivation Protects against Hepatic Cell Death and Ameliorates Fibrogenesis in a Diet-Induced NASH Model. Dig Dis Sci, 2014;59(6):1197-1206.
[27] Hatting M, Zhao G, Schumacher F, et al. Hepatocyte Caspase-8 Is an Essential Modulator of Steatohepatitis in Rodents. Hepatology, 2013,57(6):2189-2201.
[28] Barreyro FJ, Holod S, Finocchietto PV, et al. The Pan-Caspase Inhibitor Emricasan (IDN-6556) Decreases Liver Injury and Fibrosis in a Murine Model of Non-Alcoholic Steatohepatitis. Liver Int, 2015,35(3):953-966.
[29] Harrison S A , Goodman Z , Jabbar A , et al.A Randomized, Placebo-Controlled Trial of Emricasan in Patients with NASH and F1-F3 Fibrosis. J Hepatol, 2020,72(5):816-827.
[30] Gautheron J , Vucur M , Luedde T. Necroptosis in nonalcoholic steatohepatitis. Cell Mol Gastroenterol Hepatol, 2015,1(3):264-265.
[31] Roychowdhury S, McCullough RL, Sanz-Garcia C, et al.Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury. Hepatology, 2016,64(5):1518-1533.
[32] Preston SP , Stutz MD, Allison CC, et al. Epigenetic Silencing of RIPK3 in Hepatocytes Prevents MLKL-mediated Necroptosis From Contributing to Liver Pathologies. Gastroenterology, 2022,163(6):1643-1657. |
